EASi-HF

a Phase III double-blind, randomised, parallel group superority trial to evaluate efficacy and safety of the combined used of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in patients with heart failure NYHA II-IV and LVEF > 40%

Stage: inclusie
Medicine: BI690517
Population: Hartfalen
Phase: III
First Patient In: 15 January 2025
Last Patient In: 1 March 2026
Last Patient Last Visit: 4 November 2027

Inclusion period, 92 days remaining

National Lead

J.M. ter Maaten

Study Director

dr M.E. Emans

Cardioloog

Office Contact

M.J. van Doorn

WCN